Medivir: Phase IIa interferon free combination hepatitis C trial of Simeprevir (TMC435) and TMC647055
Medivir AB announced that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.
Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III clinical development for the treatment of chronic hepatitis C jointly developed by Medivir and Janssen Research & Development Ireland (Janssen). TMC647055 is a potent NNI (non-nucleoside inhibitor) of the HCV NS5B polymerase and is being developed by Janssen R&D.
“This study is in line with Medivir’s and Janssen’s strategy to evaluate different combination possibilities with simeprevir for interferon-free HCV treatments. This will broaden our understanding of simeprevir, which we believe has the necessary characteristics to potentially become a key component of future hepatitis C treatment regimens, including combination with interferon and ribavirin as well as interferon-free therapies,” comments Charlotte Edenius, Medivir’s EVP of Research and Development.
This will be an open label study in patients who are chronically infected with HCV genotype-1a or 1b to assess the efficacy, safety and tolerability of the combination. The primary endpoint in the study will be SVR12 (sustained virologic response 12 weeks after end of treatment). Simeprevir, TMC647055 and low-dose ritonavir will be co-administered once daily, with and without ribavirin.
Approximately 40 patients will be enrolled in this study, which is divided in two parts. The first part will include patients chronically infected with HCV genotype-1, who are either treatment-naive or have relapsed after prior pegylated interferon (PegIFN)/ribavirin treatment. The treatment will consist of simeprevir, TMC647055 and low-dose ritonavir, with and without ribavirin for 12 weeks.
The second part of the trial will investigate the same regimen in prior null responder patients chronically infected with HCV genotype 1a.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Basilea Reports Positive Phase III Results for Alitretinoin

Identifying Another Piece in the Parkinson's Disease Pathology Puzzle - International Consortium Identifies and Validates Cellular Role of Priority Parkinson’s Disease Drug Target, LRRK2 Kinase

Evonik invests in start-ups - Evonik More Than Doubles Venture Capital to Accelerate Innovation

French start-up to advance development of automated microfluidic cell and gene therapy manufacturing platform - Astraveus raises €16.5 Million Series Seed round
Saint_Anthony's_fire
Cenix BioScience Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery
Ectopic_pregnancy
BioMerieux Opens a Subsidiary in the Middle East, Continuing its International Growth

Merck and Japanese start-up launch collaboration - Both companies to accelerate development and manufacturing of viral vector-based gene therapy applications
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
